These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Design and synthesis of a biotinylated probe of COX-2 inhibitor nimesulide analog JCC76. Zhong B; Lama R; Smith KM; Xu Y; Su B Bioorg Med Chem Lett; 2011 Sep; 21(18):5324-7. PubMed ID: 21807508 [TBL] [Abstract][Full Text] [Related]
5. Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells. Su B; Chen S Bioorg Med Chem Lett; 2009 Dec; 19(23):6733-5. PubMed ID: 19854050 [TBL] [Abstract][Full Text] [Related]
6. Developments in synthesis of the anti-inflammatory drug, celecoxib: a review. Kumar V; Kaur K; Gupta GK; Gupta AK; Kumar S Recent Pat Inflamm Allergy Drug Discov; 2013 May; 7(2):124-34. PubMed ID: 23565678 [TBL] [Abstract][Full Text] [Related]
7. Novel benzenesulfonamide and 1,2-benzisothiazol-3(2H)-one-1,1-dioxide derivatives as potential selective COX-2 inhibitors. Taher ES; Ibrahim TS; Fares M; Al-Mahmoudy AMM; Radwan AF; Orabi KY; El-Sabbagh OI Eur J Med Chem; 2019 Jun; 171():372-382. PubMed ID: 30928709 [TBL] [Abstract][Full Text] [Related]
8. Coumarin Derivatives as Anti-inflammatory and Anticancer Agents. Thomas V; Giles D; Basavarajaswamy GPM; Das AK; Patel A Anticancer Agents Med Chem; 2017; 17(3):415-423. PubMed ID: 27592545 [TBL] [Abstract][Full Text] [Related]
9. Comparative Evaluation of Nimesulide-Loaded Nanoparticles for Anticancer Activity Against Breast Cancer Cells. Sengel-Turk CT; Hascicek C; Bakar F; Simsek E AAPS PharmSciTech; 2017 Feb; 18(2):393-403. PubMed ID: 27007742 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Famaey JP Inflamm Res; 1997 Nov; 46(11):437-46. PubMed ID: 9427063 [TBL] [Abstract][Full Text] [Related]
11. From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation. Zhong B; Cai X; Chennamaneni S; Yi X; Liu L; Pink JJ; Dowlati A; Xu Y; Zhou A; Su B Eur J Med Chem; 2012 Jan; 47(1):432-444. PubMed ID: 22119125 [TBL] [Abstract][Full Text] [Related]
12. Methylene-bearing sulfur-containing cyanopyrimidine derivatives for treatment of cancer: Part-II. Akhtar W; Nainwal LM; Kaushik SK; Akhtar M; Shaquiquzzaman M; Almalki F; Saifullah K; Marella A; Alam MM Arch Pharm (Weinheim); 2020 May; 353(5):e1900333. PubMed ID: 32115728 [TBL] [Abstract][Full Text] [Related]
13. Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors. Bechmann N; Kniess T; Köckerling M; Pigorsch A; Steinbach J; Pietzsch J Bioorg Med Chem Lett; 2015 Aug; 25(16):3295-300. PubMed ID: 26081289 [TBL] [Abstract][Full Text] [Related]